ClinicalTrials.gov
public full text
Public Domain
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
This is an open label, multi-center, randomized phase I/II study of MLN0128 versus standard sorafenib. Eligible subjects in the phase I trial will receive MLN0128 in escalating doses. Eligible subjects in the phase II trial will be 1:1 randomized to either the MLN0128 arm or the sorafenib arm.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trial of TRC105 and Sorafenib in Patients With HCC#811884
- RDEA119 and Sorafenib Combination Dose Escalation Study#883247
- Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer#1151045
- Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer#628526
- A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC#906306
Record · ID 880171
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive